OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced positive five-year Overall Survival (OS) data from the Phase I trial evaluating the company’s universal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results